Surmodics (SRDX)
(Delayed Data from NSDQ)
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.20 USD
-0.17 (-0.44%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $38.21 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.
PRGO or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PRGO vs. SRDX: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Are Options Traders Betting on a Big Move in Surmodics (SRDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Surmodics (SRDX) stock based on the movements in the options market lately.
Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller
by Zacks Equity Research
Zacks.com featured highlights include: LexinFintech, Veeco, Helen of Troy, Surmodics and Herman Miller
Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Analyst Coverage Puts Spotlight on These 5 Stocks
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
by Zacks Equity Research
Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
5 Stocks to Keep an Eye on as Analysts Initiate Coverage
by Shrabana Mukherjee
More analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.
BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost
by Zacks Equity Research
Becton, Dickinson (BDX) receives a number of regulatory approvals of late.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) makes a few lucrative acquisitions in recent times.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.
Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.
Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.
Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.
Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts
by Zacks Equity Research
Bruker's (BRKR) CALID and NANO groups hold promise.
Here's Why Investors Should Buy DexCom (DXCM) Stock Now
by Zacks Equity Research
Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.